Feedback / Questions
RLS-1496 - Rubedo Life Sci
https://www.businesswire.com/news/home/20250522955270/en/Rubedo-Life-Sciences-Announces-First-Patient-Dosed-with-Lead-Drug-Candidate-RLS-1496-the-First-GPX4-Modulator-Targeting-Pathologic-Senescent-Cells-To-Enter-Phase-1-Clinical-Trial?utm_campaign=shareaholic&utm_medium=linkedin&utm_source=socialnetwork
May 22, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next